Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

3M Elects Two New Members To The Board – $MMM $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, 3M (MMM) has appointed Pedro J. Pizarro, president and CEO of Edison International, and Anne H. Chow, retired CEO of AT&T Business to 3M’s Board of Directors, effective Feb. 9, 2023, increasing the Board size from 11 to 13 members. Anne Chow’s has over over three decades of experience in the technology and business sectors, and has served as the CEO of AT&T Business from 2019 to 2022.

Pedro Pizarro has served as President and CEO of Edison International, the parent company of Southern California Edison (SCE) since 2016. 

“We are very pleased to further strengthen 3M’s board with two highly accomplished, world-class leaders. Anne has decades of experience in technology and business, and a proven track record of transforming global organizations and community engagement. Pedro brings skills and experience in leading large companies and driving strategic improvements, and a deep understanding of the power of materials science to improve the world. They will provide invaluable insight and perspective to our board as we continue to position 3M for the future,” stated 3M chairman and CEO Mike Roman

3M (MMM) is a global science company that seems to never stop inventing. Using 46 technology platforms, their integrated team of scientists and researchers works with customers to create breakthroughs. Their inventions have improved daily life for hundreds of millions of people all over the world. With $30 billion in sales, 90,000 employees connect with customers all around the world. Scientists, researchers, and marketers work across countries and across subjects to solve challenges big and small. To learn more about 3M (MMM) and to track its ongoing progress please visit the  Vista Partners 3M (MMM), Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

Approximately 1 in 8 women and one in 1,000 men will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. The American Cancer Society (ACS) estimates that approximately 270,000 women will be diagnosed with breast cancer in the United States this year. It is the second leading cause of cancer death in American women. Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Atossa is  developing a drug “(Z)-endoxifen” to reduce mammographic breast density and, for patients who have recently been diagnosed with the most common type of breast cancer, to reduce tumor activity prior to surgery.  

On Wednesday Jan., 25, Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:


Steven C. Quay, M.D., Ph.D, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS)


2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer program with our patented (Z)-endoxifen, the highest potency Selective Estrogen Receptor Modifier (SERM). We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need. Our goal is to both help reduce the incidence of breast cancer and change the treatment paradigm for patients who are not benefiting from currently approved drugs.

In October 2022, the U.S. Food and Drug Administration (FDA) authorized the initiation of our EVANGELINE study, a Phase 2 trial of (Z)-endoxifen and Exemestane + Goserelin as neoadjuvant treatment in premenopausal women with ER+/HER2- breast cancer. While there are several FDA-approved neoadjuvant therapies for ER- breast cancers, few exist for the ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States.


(Read Original Story: Anne Chow and Pedro Pizarro elected to 3M Board of Directors in PR Newswire)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us